Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Parallel-Group, Randomized, 10-Week, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 mg of DVS SR in the Treatment of Peri- and Postmenopausal Women With Major Depressive Disorder

Next Previous
Search
Trial Profile

A Multicenter, Parallel-Group, Randomized, 10-Week, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 mg of DVS SR in the Treatment of Peri- and Postmenopausal Women With Major Depressive Disorder

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Desvenlafaxine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Pfizer; Wyeth

    • Most Recent Events

    • 16 Aug 2017 Results (n=4279) of post-hoc pooled analysis of this and other eight double blind, placebo controlled studies, published in the Journal of Clinical Psychopharmacology.
    • 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
    • 09 Jan 2012 Actual patient number is changed from 463 to 439 according to ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top